SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : ajtj's Post-Lobotomy Market Charts and Thoughts -- Ignore unavailable to you. Want to Upgrade?


To: ajtj99 who wrote (84956)3/10/2024 6:07:56 PM
From: Tweets Boar Hog1 Recommendation

Recommended By
ajtj99

  Respond to of 97962
 
Hit the low close enuff. Got what I wanted for now, plan to trade it some. Hopefully as it goes up.

This one could over time do really well.

Following Sava. No present position. Fuzzy insight as to next major low. Maybe last quarter. It dumped end of week, I think it goes on down, we C. No revenue yet, the market has not been real kind to those sorts.

Shares of Cassava Sciences Inc. plunged 21.0% in trading on Wednesday after that the Justice Department is investigating whether the company manipulated clinical data for a still-investigational Alzheimer's disease drug,...

High risk but can be high reward sector.

Thanks aj.

Tweets



To: ajtj99 who wrote (84956)4/16/2024 8:50:38 PM
From: last2no2  Read Replies (1) | Respond to of 97962
 
You were right on this call for NVAX is it still a buy.
las2no2



To: ajtj99 who wrote (84956)4/16/2024 9:15:35 PM
From: Sun Tzu  Respond to of 97962
 
How does a company end up with negative book value?
How long can NVAX defer its taxes?